前導性化學治療對於膀胱泌尿上皮腫瘤之臨床成果報告
羅敏誠、張英勛、莊正鏗、馮思中、林柏宏、劉忠一
林口長庚紀念醫院 外科部 泌尿科
The clinical efficacy of neoadjuvant chemotherapy on urothelial carcinoma of the bladder: A retrospective analysis from a Single-center in Taiwan
Ming Cheng Luo, Ying-Hsu Chang、Cheng-Keng Chuang、, See-Tong Pang、Po-Hung Lin、Chung-Yi Liu
Divisions of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan
Purpose: Current evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. We intend to compare clinical outcomes in patients treated for MIBC with neoadjuvant chemotherapy at our institution.
Materials and Methods: We retrospectively reviewed total 26 patients received neoadjuvant chemotherapy from Jan.2012 to Feb.2016 in Linkou Chang Gung Memorial Hospital. Twenty of 26 patients completed neoadjuvant chemotherapy, followed by radical cystectomy and urothelial bladder carcinoma was pathologically proven.
Results: The median time from diagnosis to operation is 3.45 months(1.38-3.65). Two of 20(10%) patients have pathological complete response, Ten of 20(50%) patients have partial response and Two of 20(10%) have stable disease. The mean time of disease free survival (time from surgery to recurrence) is 22.47 months. The mean time of overall survival (time from surgery to recurrence) is 25.72 months. Conclusions: Our data revealed that neoadjuvant chemotherapy in bladder cancer have 10% complete response rate and significant downstaging of urothelial carcinoma with 60%. However, more such studies with larger sample sizes and longer follow-ups are needed and we intend to standardize the regimen of neoadjuvant chemotherapy to evaluate the efficacy much precise.